AstraZeneca Earlier Announced Imfinzi Plus Bevacizumab Met Primary Endpoint For Progression-free Survival In Liver Cancer
Portfolio Pulse from Charles Gross
AstraZeneca announced positive results from the EMERALD-1 Phase III trial of its drug Imfinzi in combination with transarterial chemoembolisation (TACE) and bevacizumab for liver cancer. The trial showed a significant improvement in progression-free survival (PFS) versus TACE alone.
November 09, 2023 | 9:54 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
AstraZeneca's positive trial results for Imfinzi could potentially boost its stock in the short term.
Positive clinical trial results often lead to increased investor confidence, which can drive up the stock price. Given that this is a Phase III trial, the final stage before FDA approval, the impact could be significant.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100